CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MYND Life Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MYND Life Sciences Inc
105-2248 Elgin Ave
Phone: (780) 965-0122p:780 965-0122 PORT COQUITLAM, BC  V3C 2B2  Canada Ticker: MYNDMYND
Business Summary
MYND Life Sciences Inc. is a Canada-based life science based, neuro-pharmaceutical drug development company. The Company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials, with an initial focus on major depressive disorder (MDD). Its lead development program, referred to as the human mycogene modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin and/or its analogs. It is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions as well as multiple sclerosis, and Alzheimer’s disease. Its programs include MYND-604 and MYND-778.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
7/31/202410/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board LyleOberg 12/5/2023 11/26/2020
Chief Financial Officer PaulCiullo 11/26/2020 11/26/2020
Chief Operating Officer JordanCleland 11/26/2020 11/26/2020
5 additional Officers and Directors records available in full report.

Business Names
Business Name
MYND
MYNDF

General Information
Outstanding Shares: 47,817,182 (As of 7/31/2024)
Stock Exchange: CNQ
Email Address: info@myndsciences.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025